Irbm-science Park S.p.a.

A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Bristol Myers Squibb S.p.a.

C.n.c.c.s. Scarl Collezione Nazionale Dei Composti Chimici E Centro Screening

Edith Monteagudo

Vincenzo Summa

Steven Harper

Emanuela Nizi

Ralph Laufer

Alberto Bresciani

Sergio Altamura

Federico Maria Arcamone

Paolo Lombardi

Giuseppe Giannini

Jesus Maria Ontoria Ontoria

Roberto Gambari

Paola Pace

Federica Ferrigno

Simona Ponzi

Fabio Animati

Savina Malancona

Ilaria Biancofiore

Giacomo Paonessa

Maria Vittoria Orsale

Maria Veneziano

Danilo Fabbrini

Giulia Breveglieri

The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like &#x3b2;-thalassemia or sickle cell anemia. 

Compounds for use in the treatment of disorders that are ameliorated by inhibition of HDAC

The present invention relates to compounds useful for treating parasitic diseases, which are infectious diseases caused or transmitted by a parasite. Compounds of the invention are particularly active against the causative pathogens in malaria. Such compounds are selective inhibitors of parasitic histone deacetylase (PfHDAC) and suppress the growth of parasites, such as, at a lower concentration than the concentration required for the inhibition of the growth of mammalian cells.

Compounds for use in the treatment of parasitic diseases

S-fluoro-anthracyclines, processes for their preparation and

Growing community of inventors

Pomezia, Italy

Edith Monteagudo